PMC:7299399 / 14059-14797 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T68","span":{"begin":398,"end":405},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T61","span":{"begin":324,"end":332},"obj":"Disease"}],"attributes":[{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T164","span":{"begin":13,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T165","span":{"begin":216,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T166","span":{"begin":269,"end":274},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T167","span":{"begin":305,"end":306},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T168","span":{"begin":333,"end":337},"obj":"http://purl.obolibrary.org/obo/CLO_0001236"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T80","span":{"begin":81,"end":84},"obj":"Chemical"},{"id":"T81","span":{"begin":239,"end":253},"obj":"Chemical"},{"id":"T82","span":{"begin":239,"end":248},"obj":"Chemical"},{"id":"T83","span":{"begin":249,"end":253},"obj":"Chemical"},{"id":"T84","span":{"begin":307,"end":311},"obj":"Chemical"},{"id":"T85","span":{"begin":349,"end":358},"obj":"Chemical"},{"id":"T86","span":{"begin":398,"end":405},"obj":"Chemical"},{"id":"T87","span":{"begin":535,"end":545},"obj":"Chemical"},{"id":"T88","span":{"begin":674,"end":679},"obj":"Chemical"}],"attributes":[{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"LitCovid-sentences","denotations":[{"id":"T68","span":{"begin":0,"end":738},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"LitCovid-PubTator","denotations":[{"id":"238","span":{"begin":436,"end":440},"obj":"Gene"},{"id":"239","span":{"begin":390,"end":391},"obj":"Gene"},{"id":"240","span":{"begin":392,"end":397},"obj":"Gene"},{"id":"241","span":{"begin":324,"end":334},"obj":"Species"},{"id":"242","span":{"begin":626,"end":634},"obj":"Species"},{"id":"244","span":{"begin":604,"end":612},"obj":"Disease"}],"attributes":[{"id":"A238","pred":"tao:has_database_id","subj":"238","obj":"Gene:59272"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"Gene:43740568"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"Gene:43740568"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"Tax:2697049"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"Tax:9606"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}

{"project":"2_test","denotations":[{"id":"32519842-29251725-158477","span":{"begin":254,"end":256},"obj":"29251725"},{"id":"32519842-32015507-158478","span":{"begin":450,"end":452},"obj":"32015507"},{"id":"32519842-32333836-158479","span":{"begin":453,"end":455},"obj":"32333836"},{"id":"32519842-32142651-158480","span":{"begin":456,"end":458},"obj":"32142651"}],"text":"Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.19,21−23 Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to receive those drugs for extended periods of time and will already be weakened."}